Boston Scientific Announces First Patient Enrollment in MultiSENSE Clinical Trial

NATICK, Massachusetts, July 8, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced
enrollment of the first patient in its MultiSENSE clinical trial. The trial
is designed to evaluate multiple physiologic sensors in the Company's
COGNIS(TM) cardiac resynchronization therapy defibrillators (CRT-Ds). Boston
Scientific plans to use the trial data to help develop a clinical alert that
identifies the early onset of worsening heart failure. The first patient was
enrolled by Paul Coffeen, M.D., Austin Heart, Austin, Texas, where Jeffrey
Whitehill, M.D., Medical Chair, Electrophysiology Department, is the site's
Principal Investigator.

When combined with the Company's LATITUDE(R) Patient
Management System, CRT-D sensors would be able to monitor a patient outside
of a clinical setting and permit the LATITUDE system to deliver early
notification to the physician when the patient's heart failure worsens.

"Heart failure is a complex disease and physicians use a
number of diagnostics to assess a patient's condition and disease
progression," said John Boehmer, M.D., Medical Director, Heart Failure
Program and Professor of Medicine, Penn State Hershey Medical Center and
Principal Investigator of the MultiSENSE trial. "A multi-sensor design in an
implantable device, with the predictive power of multiple data points, would
enable physicians to take clinical action sooner to avoid hospitalization due
to heart failure."

"The MultiSENSE trial marks a significant step toward
addressing the unmet needs of heart failure patients," said Kenneth Stein,
M.D., Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm
and Vascular Group. "Boston Scientific's unique multi-sensor approach is
designed to allow our CRT-Ds to assess the same symptoms and data a doctor
evaluates when seeing a heart failure patient in the office."

Heart failure is a debilitating condition that affects a
patient's quality of life and life expectancy. It is a condition in which the
heart weakens and gradually loses the ability to pump blood effectively.
Approximately 22 million people worldwide suffer from heart failure and
nearly one million new cases are diagnosed annually, making it the most
rapidly growing cardiovascular disorder.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
our product performance, clinical outcomes, regulatory approval of our
products, and our growth strategy. If our underlying assumptions turn out to
be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT: 

    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    David Knutson
    +1-651-582-6574 (office)
    +1-651-260-8288 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

CONTACT: Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation; David Knutson, +1-651-582-6574 (office), +1-651-260-8288 (mobile), Media Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696, (office), Investor Relations, Boston Scientific Corporation